Medscape Oncology

The Medscape Oncologist Compensation Report 2018 reveals more about oncology practice than simple dollars and cents.

Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the potential role of immune checkpoint inhibitors in the neoadjuvant setting may be the most promising.

After an 'extraordinary week' of advances in lung cancer, Dr Mark Kris explains why checkpoint inhibitors now play a major role in lung cancer therapy.

When discussing checkpoint inhibitor adverse effects, Dr Mark Kris argues that we have to consider their potentially outsize benefits.

There is no evidence that screening actually improves outcomes in ovarian cancer, according to a USPSTF analysis of the best available data.

Dr David Kerr shares thoughts on the 100,000 Genomes project linking whole genome sequencing to outcomes and the skepticism among some colleagues about the benefits of so-called actionable mutations.

Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted for daily subcutaneous dalteparin in cancer patients who have had a venous thromboembolism.

Dr David Kerr on how the recent case for DPYD screening may be on (and off) mark in addressing chemotherapy toxicity.

Dr David J. Kerr discusses the difficult task of delivering bad news to patients--and their often paradoxical response--by sharing one of his favorite poems by Raymond Carver

Dr David Kerr on how combining ploidy and stroma-tumor fraction can guide treatment decisions in patients with stage II disease.